Posted by Michael Wonder on 27 Jan 2022
TGA approves Tepmetko for patients with non-small-cell lung cancer
27 January 2022 - Tepotinib (Tepmetko) has provisional approval in Australia for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
The decision to approve this indication has been made on the basis of overall response rate and duration of response. Continued approval of this indication depends on verification and description of benefit in confirmatory trial(s).
